Stockscreener 앱 받기
21.70
0.37%
-0.08
시장 영업 전:
22.32
0.62
+2.86%
전일 마감가:
$21.78
열려 있는:
$21.89
하루 거래량:
1.76M
Relative Volume:
1.40
시가총액:
$3.21B
수익:
$460.48M
순이익/손실:
$142.80M
주가수익비율:
18.39
EPS:
1.18
순현금흐름:
$221.79M
1주 성능:
-1.90%
1개월 성능:
-13.06%
6개월 성능:
+3.98%
1년 성능:
+40.09%
1일 변동 폭
$21.51
$22.07
1주일 범위
$21.40
$22.54
52주 변동 폭
$14.97
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
명칭
Catalyst Pharmaceuticals Inc
전화
(305) 529-2522
주소
355 ALHAMBRA CIRCLE, CORAL GABLES
CPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
21.70 | 3.21B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Robert W. Baird | Outperform |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-03-14 | 개시 | Citigroup | Buy |
| 2024-03-07 | 개시 | BofA Securities | Buy |
| 2023-12-21 | 개시 | Oppenheimer | Outperform |
| 2022-08-24 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 재개 | Piper Jaffray | Overweight |
| 2016-10-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 재확인 | ROTH Capital | Buy |
| 2014-09-16 | 재확인 | ROTH Capital | Buy |
| 2014-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2013-10-21 | 재확인 | Aegis Capital | Buy |
| 2013-09-24 | 개시 | Maxim Group | Buy |
| 2013-09-06 | 재확인 | Aegis Capital | Buy |
| 2013-04-18 | 개시 | Aegis Capital | Buy |
| 2012-08-27 | 업그레이드 | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | 업그레이드 | Merriman | Sell → Neutral |
| 2009-05-29 | 다운그레이드 | Hapoalim | Neutral → Underperform |
| 2009-05-29 | 다운그레이드 | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 개시 | Merriman Curhan Ford | Buy |
| 2007-11-28 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 개시 | Stifel Nicolaus | Buy |
| 2007-01-05 | 개시 | First Albany | Buy |
모두보기
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Reports Strong Q1 2025 Earnings Growth - Yahoo Finance
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - Yahoo Finance
Stanley Laman Group Ltd. Acquires New Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
GAMMA Investing LLC Has $1.64 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading Down 5.2% Following Insider Selling - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells $42,272.00 in Stock - MarketBeat
Trading (CPRX) With Integrated Risk Controls - news.stocktradersdaily.com
Preethi Sundaram Implements A Sell Strategy: Offloads $103K In Catalyst Pharmaceuticals Stock - Nasdaq
Wesbanco Bank Inc. Invests $461,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Insider Sell: Preethi Sundaram Sells Shares of Catalyst Pharmaceuticals Inc (CPRX) - GuruFocus
Preethi Sundaram Sells 2,324 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock - MarketBeat
117,374 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Bought by Bridge City Capital LLC - MarketBeat
Director Of Catalyst Pharmaceuticals Sold $5.22M In Stock - Nasdaq
Insider Sell: Patrick Mcenany Sells 200,000 Shares of Catalyst P - GuruFocus
Catalyst Pharmaceuticals, Inc. (CPRX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Catalyst Pharmaceuticals stock soars to all-time high of $26.49 By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals stock soars to all-time high of $26.49 - Investing.com Australia
Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded by Cantor Fitzgerald to "Strong-Buy" Rating - MarketBeat
Catalyst (CPRX) Up 11.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance
If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now - MSN
Catalyst Pharmaceuticals (CPRX) CEO Acquires 70,000 Shares | CPR - GuruFocus
What Makes Catalyst Pharmaceutical (CPRX) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Insider Sell: Richard Daly Sells 70,000 Shares of Catalyst Pharm - GuruFocus
Catalyst Pharmaceuticals (CPRX) CEO Acquires 70,000 Shares | CPRX Stock News - GuruFocus
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Appoints Dr. William Andrews As New Chief Medical Officer - Yahoo Finance
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term - Yahoo Finance
Catalyst Pharmaceuticals names new Chief Medical Officer By Investing.com - Investing.com South Africa
Catalyst Pharma Appoints New Chief Medical Officer - TipRanks
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer - GlobeNewswire
Catalyst Pharmaceuticals names new Chief Medical Officer - Investing.com
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance
Catalyst Pharmaceuticals (CPRX) Names New Chief Medical Officer | CPRX Stock News - GuruFocus
Catalyst Pharmaceuticals Announces Appointment of William T. And - GuruFocus
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer | CPRX Stock News - GuruFocus
Catalyst Pharmaceuticals Taps Harvard-Yale Veteran with 18 Years Rare Disease Expertise as New CMO - Stock Titan
What is Zacks Research’s Forecast for CPRX FY2025 Earnings? - Defense World
(CPRX) Trading Report - news.stocktradersdaily.com
Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma (NASDAQ:CPRX) - Seeking Alpha
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Zacks Research Brokers Raise Earnings Estimates for CPRX - Defense World
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings Are Not Doing Enough For Some Investors - simplywall.st
ProShare Advisors LLC Boosts Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
D. E. Shaw & Co. Inc. Buys Shares of 18,173 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Position Decreased by Jane Street Group LLC - Defense World
Cetera Investment Advisers Grows Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Ameriprise Financial Inc. Grows Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Transcript : Catalyst Pharmaceuticals, Inc.Shareholder/Analyst Call - marketscreener.com
Catalyst Pharmaceuticals at Bank of America 2025: Strategic Expansion and Growth - Investing.com Canada
Transcript : Catalyst Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08 - marketscreener.com
The Strong Earnings Posted By Catalyst Pharmaceuticals (NASDAQ:CPRX) Are A Good Indication Of The Strength Of The Business - Yahoo Finance
Catalyst Pharmaceuticals Inc (CPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Catalyst Pharmaceuticals Inc 주식 (CPRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sundaram Preethi | Chief Strategy Officer |
Jun 11 '25 |
Sale |
26.42 |
1,600 |
42,272 |
41,081 |
0.78%
0.23%
자본화:
|
볼륨(24시간):